NCT05777278View on ClinicalTrials.gov

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 26, 2023

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Savolitinib

Savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID)

DRUG

Docetaxel

Docetaxel (60 mg/m2, ivgtt, q3w)

Trial Locations (1)

Unknown

RECRUITING

Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER